{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:13:47Z","timestamp":1792059227885,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.parkreldis.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T13:30:16Z","timestamp":1532093416000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort"],"prefix":"10.1016","volume":"57","author":[{"given":"Benoit","family":"Peyronnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Vurture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-6774","authenticated-orcid":false,"given":"Jose-Alberto","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique R.","family":"Malacarne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael D.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton C.","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Palmerola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirit","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Frucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.","family":"Nitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.07.005_bib1","series-title":"National Collaborating Centre for Chronic Conditions: Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care","first-page":"121","year":"2006"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.07.005_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrurol.2016.254","article-title":"Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy","volume":"14","author":"Ogawa","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ucl.2017.04.008","article-title":"Parkinson's disease and its effect on the lower urinary tract","volume":"44","author":"Brucker","year":"2017","journal-title":"Urol. Clin."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.07.005_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bju.13187","article-title":"Guideline of guidelines: urinary incontinence","volume":"117","author":"Syan","year":"2016","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.07.005_bib5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euf.2018.04.005","article-title":"Lower urinary tract symptoms: what's new in medical treatment","volume":"4","author":"Peyronnet","year":"2018","journal-title":"Eur. Urol. Focus"},{"issue":"12","key":"10.1016\/j.parkreldis.2018.07.005_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2018.07.005_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The unified Parkinson's disease rating scale (UPDRS): status and recommendations","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease","year":"2003","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2018.07.005_bib9","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib10","author":"Foods and Drugs Administration"},{"key":"10.1016\/j.parkreldis.2018.07.005_bib11","author":"Abrams"},{"key":"10.1016\/j.parkreldis.2018.07.005_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/nau.23717","article-title":"Outcomes of intradetrusor botulinum toxin injection in patients with Parkinson's disease","author":"Vurture","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","article-title":"Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management","volume":"35","author":"McDonald","year":"2017","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.07.005_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mds.27344","article-title":"Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies","volume":"33","author":"Palma","year":"2018","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.07.005_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.22764","article-title":"A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders","volume":"35","author":"Sakakibara","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/nau.23506","article-title":"Is there \"brain OAB\" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017","author":"Apostolidis","year":"2018","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","article-title":"Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease","volume":"21","author":"Zesiewicz","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.03.009","article-title":"Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPi)","volume":"27","author":"Murchison","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.07.005_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/mds.26595","article-title":"Atropinic (anticholinergic) burden in Parkinson's disease","volume":"31","author":"De Germay","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib20","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","volume":"2","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2015.10.002","article-title":"Systematic review on the use of anticholinergic scales in polypathological patients","volume":"62","author":"Villalba-Moreno","year":"2016","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"14","key":"10.1016\/j.parkreldis.2018.07.005_bib22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carriere","year":"2009","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.07.005_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.parkreldis.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00192-014-2548-x","article-title":"Impact of anticholinergic load on bladder function","volume":"26","author":"De La Cruz","year":"2015","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.parkreldis.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejogrb.2016.12.030","article-title":"Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study","volume":"210","author":"Martan","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/iju.13422","article-title":"Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis","volume":"24","author":"Kato","year":"2017","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.parkreldis.2018.07.005_bib27","first-page":"e25","article-title":"Persistence with mirabegron versus tolterodine in patients with overactive bladder","volume":"8","author":"Nitti","year":"2016","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.parkreldis.2018.07.005_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/luts.12188","article-title":"Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: interim (1-year) report from a Japanese post-marketing surveillance study","author":"Kato","year":"2017","journal-title":"Low. Urin. Tract. Symptoms"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.07.005_bib29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","article-title":"Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder","volume":"32","author":"Chapple","year":"2014","journal-title":"World J. Urol."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018303080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018303080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T16:44:00Z","timestamp":1545065040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018303080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"alternative-id":["S1353802018303080"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}